BRPI1008936B8 - método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano - Google Patents
método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humanoInfo
- Publication number
- BRPI1008936B8 BRPI1008936B8 BRPI1008936A BRPI1008936A BRPI1008936B8 BR PI1008936 B8 BRPI1008936 B8 BR PI1008936B8 BR PI1008936 A BRPI1008936 A BR PI1008936A BR PI1008936 A BRPI1008936 A BR PI1008936A BR PI1008936 B8 BRPI1008936 B8 BR PI1008936B8
- Authority
- BR
- Brazil
- Prior art keywords
- prognosis
- diagnosis
- vitro method
- fibrosis
- predisposition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
método in vitro para detectar pré-disposição, diagnóstico e / ou prognóstico de fibrose e método de seleção de um composto terapêutico. a presente invenção revela a identificação de um locus do gene de suceptibilidade á fribose, o locus do gene ctgf,que pode ser usado para detectar predisposto a, dignóstico e prognóstico de fibrose, bem como para o rastreamento de medicamentos terapeuticamente ativos. a invenção reside, em uma amostra de indivíduo de presença de uma alteração no locus do gene ctgf, a presença da dita alteração sendo indicativa da presença ou predisposto á fibrose.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09305159A EP2221387A1 (en) | 2009-02-19 | 2009-02-19 | Fibrosis susceptibility gene and uses thereof |
EP093051597 | 2009-02-19 | ||
PCT/EP2010/052048 WO2010094740A1 (en) | 2009-02-19 | 2010-02-18 | Fibrosis susceptibility gene and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI1008936A2 BRPI1008936A2 (pt) | 2016-10-11 |
BRPI1008936B1 BRPI1008936B1 (pt) | 2021-04-06 |
BRPI1008936B8 true BRPI1008936B8 (pt) | 2021-07-27 |
Family
ID=40568438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1008936A BRPI1008936B8 (pt) | 2009-02-19 | 2010-02-18 | método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano |
Country Status (8)
Country | Link |
---|---|
US (2) | US9297044B2 (pt) |
EP (2) | EP2221387A1 (pt) |
JP (2) | JP5837825B2 (pt) |
KR (1) | KR101748679B1 (pt) |
CN (2) | CN102325904B (pt) |
BR (1) | BRPI1008936B8 (pt) |
CA (1) | CA2752802C (pt) |
WO (1) | WO2010094740A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012085217A1 (en) * | 2010-12-22 | 2012-06-28 | Universite De La Mediterranee (Aix-Marseille Ii) | A diagnostic method for dementias |
US10150989B2 (en) | 2011-08-05 | 2018-12-11 | Universite D'aix Marseille | Fibrosis susceptibility IL22RA2 gene and uses thereof |
ES2422874B1 (es) * | 2012-03-12 | 2014-07-15 | Universidad Autnoma De Madrid | Método in vitro de pronóstico de fibrosis hepática grave |
CN110719958B (zh) * | 2017-04-06 | 2023-07-18 | 康博国际有限公司 | 构建核酸文库的方法和试剂盒 |
EP3425056A1 (en) * | 2017-07-07 | 2019-01-09 | Genepred Biotechnologies | Method for prognosing fibrosis progression |
EP3864175A1 (en) | 2018-10-11 | 2021-08-18 | Genepred Biotechnologies | Method for detecting fibrosis especially keloid |
CN111073884A (zh) * | 2020-02-14 | 2020-04-28 | 昆明理工大学 | 提高非编码区域距离<50bp的SNP中具有功能效应的SNP位点检测准确率的方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770209A (en) * | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
EP0730663B1 (en) | 1993-10-26 | 2003-09-24 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
JP4226471B2 (ja) * | 2001-09-18 | 2009-02-18 | ファイブローゲン、インコーポレーテッド | 結合組織増殖因子の分析方法 |
US7405274B2 (en) * | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
GB0326780D0 (en) | 2003-11-18 | 2003-12-24 | Imp College Innovations Ltd | Biological materials and uses thereof |
AU2007328206B2 (en) * | 2006-12-04 | 2013-08-01 | Promedior, Inc. | Conjoint therapy for treating fibrotic diseases |
CA2797782A1 (en) | 2010-05-04 | 2011-11-10 | Universite D'aix-Marseille | Antiviral treatment susceptibility gene and uses thereof |
US10150989B2 (en) | 2011-08-05 | 2018-12-11 | Universite D'aix Marseille | Fibrosis susceptibility IL22RA2 gene and uses thereof |
-
2009
- 2009-02-19 EP EP09305159A patent/EP2221387A1/en not_active Withdrawn
-
2010
- 2010-02-18 JP JP2011550565A patent/JP5837825B2/ja active Active
- 2010-02-18 CA CA2752802A patent/CA2752802C/en active Active
- 2010-02-18 BR BRPI1008936A patent/BRPI1008936B8/pt active IP Right Grant
- 2010-02-18 CN CN201080008683.5A patent/CN102325904B/zh active Active
- 2010-02-18 CN CN201610204906.4A patent/CN105907843A/zh active Pending
- 2010-02-18 EP EP10703912.5A patent/EP2398911B1/en active Active
- 2010-02-18 WO PCT/EP2010/052048 patent/WO2010094740A1/en active Application Filing
- 2010-02-18 KR KR1020117021902A patent/KR101748679B1/ko active IP Right Grant
- 2010-02-18 US US13/201,520 patent/US9297044B2/en active Active
-
2015
- 2015-08-21 JP JP2015164050A patent/JP2016047045A/ja active Pending
-
2016
- 2016-02-16 US US15/045,107 patent/US20160230232A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2398911B1 (en) | 2017-10-18 |
CA2752802A1 (en) | 2010-08-26 |
EP2221387A1 (en) | 2010-08-25 |
US20120135403A1 (en) | 2012-05-31 |
JP2016047045A (ja) | 2016-04-07 |
CN105907843A (zh) | 2016-08-31 |
CA2752802C (en) | 2018-04-03 |
CN102325904A (zh) | 2012-01-18 |
JP2012524520A (ja) | 2012-10-18 |
KR20120004971A (ko) | 2012-01-13 |
US9297044B2 (en) | 2016-03-29 |
US20160230232A1 (en) | 2016-08-11 |
EP2398911A1 (en) | 2011-12-28 |
BRPI1008936B1 (pt) | 2021-04-06 |
CN102325904B (zh) | 2016-03-30 |
WO2010094740A1 (en) | 2010-08-26 |
BRPI1008936A2 (pt) | 2016-10-11 |
JP5837825B2 (ja) | 2015-12-24 |
KR101748679B1 (ko) | 2017-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1008936B8 (pt) | método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano | |
BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
MX2014005710A (es) | Un metodo de cribado de farmaco y usos del mismo. | |
NO20083957L (no) | DNA-konformasjon | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
BR112013004673A8 (pt) | biomarcadores e métodos de tratamento. | |
BR112013010015A2 (pt) | aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos | |
WO2009085234A3 (en) | Use of micro-rna as a biomarker of immunomodulatory drug activity | |
EP2576833A4 (en) | METHOD AND DEVICE FOR THE POINT-OF-CARE DETECTION OF NUCLEIC ACID IN A SAMPLE | |
PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
GB201300533D0 (en) | Methods of monitoring conditions by sequence analysis | |
AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
WO2013166186A8 (en) | Method for determining complete response to anticancer therapy | |
UY32698A (es) | Marcadores de riesgo para enfermedades cardiovasculares | |
JP2014144959A5 (pt) | ||
BR112012021590A2 (pt) | detecção de capacitância em ensaio eletroquímico | |
WO2011087709A3 (en) | Eml4-alk translocations in lung cancer | |
MX2013005796A (es) | Metodos para detectar enfermedades o alteraciones neurodegenerativas. | |
BR112014009223A8 (pt) | método para o diagnóstico da doença de niemann-pick | |
NZ592994A (en) | Diagnostic test for Streptococcus equi comprising assessing the presence or absence of the S. equi eqbE gene | |
BR112014010463A2 (pt) | processo para detectar um ou mais sorotipos do vírus da dengue em uma amostra, kit para detecção da infecção por vírus da dengue, oligonucleotídeo isolado, pluralidade de oligonucleotídeos isolados, processo para diagnosticar ou confirmar o diagnóstico da presença ou ausência do vírus da dengue em um indivíduo, processo para detectar a presença ou ausência do vírus da dengue em uma amostra e uso de um primer ou sonda de ácido nucléico para preparar uma composição para diagnosticar ou confirmar a presença ou ausência do vírus da dengue em um indivíduo | |
WO2009114712A3 (en) | Assays for diagnosing and evaluating treatment options for pompe disease | |
IN2014DN08537A (pt) | ||
BR112014011937A2 (pt) | detecção altamente multiplexada quantitativa de ácidos nucléicos | |
WO2010000467A8 (en) | Asc as a marker for lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |